Authors:
Tokuda, T
Tamaoka, A
Matsuno, S
Sakurai, S
Shimada, H
Morita, H
Ikeda, S
Citation: T. Tokuda et al., Plasma levels of amyloid beta proteins did not differ between subjects taking statins and those not taking statins, ANN NEUROL, 49(4), 2001, pp. 546-547
Authors:
Ishii, K
Lippa, C
Tomiyama, T
Miyatake, F
Ozawa, K
Tamaoka, A
Hasegawa, T
Fraser, PE
Shoji, S
Nee, LE
Pollen, DA
St George-Hyslop, PH
Ii, K
Ohtake, T
Kalaria, RN
Rossor, MN
Lantos, PL
Cairns, NJ
Farrer, LA
Mori, H
Citation: K. Ishii et al., Distinguishable effects of Presenilin-1 and APP717 mutations on amyloid plaque deposition, NEUROBIOL A, 22(3), 2001, pp. 367-376
Authors:
Hoshi, K
Yoshida, K
Nakamura, A
Tada, T
Tamaoka, A
Ikeda, S
Citation: K. Hoshi et al., Cessation of cerebral hemorrhage recurrence associated with corticosteroidtreatment in a patient with cerebral amyloid angiopathy, AMYLOID, 7(4), 2000, pp. 284-288
Authors:
Tamaoka, A
Matsuno, S
Ono, S
Shimizu, N
Shoji, S
Citation: A. Tamaoka et al., Increased amyloid beta protein in the skin of patients with amyotrophic lateral sclerosis, J NEUROL, 247(8), 2000, pp. 633-635
Authors:
Cavani, S
Tamaoka, A
Moretti, A
Marinelli, L
Angelini, G
Di Stefano, S
Piombo, G
Cazzulo, V
Matsuno, S
Shoji, S
Furiya, Y
Zaccheo, D
Dagna-Bricarelli, F
Tabaton, M
Mori, H
Citation: S. Cavani et al., Plasma levels of amyloid beta 40 and 42 are independent from ApoE genotypeand mental retardation in Down syndrome, AM J MED G, 95(3), 2000, pp. 224-228
Authors:
Harada, H
Ohkoshi, N
Fujita, Y
Tamaoka, A
Shoji, S
Citation: H. Harada et al., Clinical improvement following interferon-alpha alone as an initial treatment in CIDP, MUSCLE NERV, 23(2), 2000, pp. 295-296
Authors:
Mochizuki, A
Tamaoka, A
Shimohata, A
Komatsuzaki, Y
Shoji, S
Citation: A. Mochizuki et al., A beta 42-positive non-pyramidal neurons around amyloid plaques in Alzheimer's disease, LANCET, 355(9197), 2000, pp. 42-43
Authors:
Tamaoka, A
Miyatake, F
Matsuno, S
Ishii, K
Nagase, S
Sahara, N
Ono, S
Mori, H
Wakabayashi, K
Tsuji, S
Takahashi, H
Shoji, S
Citation: A. Tamaoka et al., Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease, NEUROLOGY, 54(12), 2000, pp. 2319-2321
Authors:
Yasuda, M
Maeda, S
Kawamata, T
Tamaoka, A
Yamamoto, Y
Kuroda, S
Maeda, K
Tanaka, C
Citation: M. Yasuda et al., Novel presenilin-1 mutation with widespread cortical amyloid deposition but limited cerebral amyloid angiopathy, J NE NE PSY, 68(2), 2000, pp. 220-223
Authors:
Tamaoka, A
Sekijima, Y
Masuno, S
Tokuda, T
Shoji, S
Ikeda, SI
Citation: A. Tamaoka et al., Amyloid beta protein species in cerebrospinal fluid and in brain from patients with Down's syndrome, ANN NEUROL, 46(6), 1999, pp. 933-933
Authors:
Hu, J
Miyatake, F
Aizu, Y
Nakagawa, H
Nakamura, S
Tamaoka, A
Takahash, R
Urakami, K
Shoji, M
Citation: J. Hu et al., Angiotensin-converting enzyme genotype is associated with Alzheimer disease in the Japanese population, NEUROSCI L, 277(1), 1999, pp. 65-67
Authors:
Hoshino, S
Yoshizawa, T
Hayashi, A
Ohkoshi, N
Tamaoka, A
Shoji, S
Citation: S. Hoshino et al., A combination of autoimmune hepatitis, sensory-dominant peripheral neuropathy, and primary Sjogren's syndrome in the same patient: A rare association, J MED, 30(1-2), 1999, pp. 83-92
Authors:
Harada, H
Tamaoka, A
Kohno, Y
Mochizuki, A
Shoji, S
Citation: H. Harada et al., Exacerbation of myasthenia gravis in a patient after interferon-beta treatment for chronic active hepatitis C, J NEUR SCI, 165(2), 1999, pp. 182-183
Authors:
Christie, G
Markwell, RE
Gray, CW
Smith, L
Godfrey, F
Mansfield, F
Wadsworth, H
King, R
McLaughlin, M
Cooper, DG
Ward, RV
Howlett, DR
Hartmann, T
Lichtenthaler, SF
Beyreuther, K
Underwood, J
Gribble, SK
Cappai, R
Masters, CL
Tamaoka, A
Gardner, RL
Rivett, AJ
Karran, EH
Allsop, D
Citation: G. Christie et al., Alzheimer's disease: Correlation of the suppression of beta-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome, J NEUROCHEM, 73(1), 1999, pp. 195-204